These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 30064663)
1. Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells. Bugide S; Janostiak R; Wajapeyee N Trends Cancer; 2018 Aug; 4(8):553-566. PubMed ID: 30064663 [TBL] [Abstract][Full Text] [Related]
2. Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy. Hojjatipour T; Maali A; Azad M Epigenomics; 2023 Feb; 15(4):249-266. PubMed ID: 37125432 [TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. Naeimi Kararoudi M; Tullius BP; Chakravarti N; Pomeroy EJ; Moriarity BS; Beland K; Colamartino ABL; Haddad E; Chu Y; Cairo MS; Lee DA Semin Hematol; 2020 Oct; 57(4):201-212. PubMed ID: 33256913 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of natural killer cells for cancer immunotherapy. Miyazato K; Hayakawa Y Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190 [TBL] [Abstract][Full Text] [Related]
5. The role of natural killer cells in cancer therapy. Lee SK; Gasser S Front Biosci (Elite Ed); 2010 Jan; 2(2):380-91. PubMed ID: 20036886 [TBL] [Abstract][Full Text] [Related]
6. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. Islam R; Pupovac A; Evtimov V; Boyd N; Shu R; Boyd R; Trounson A Cells; 2021 Apr; 10(5):. PubMed ID: 33946954 [TBL] [Abstract][Full Text] [Related]
7. Purinergic targeting enhances immunotherapy of CD73 Wang J; Lupo KB; Chambers AM; Matosevic S J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403 [TBL] [Abstract][Full Text] [Related]
8. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Ames E; Murphy WJ Cancer Immunol Immunother; 2014 Jan; 63(1):21-8. PubMed ID: 23989217 [TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Hu W; Wang G; Huang D; Sui M; Xu Y Front Immunol; 2019; 10():1205. PubMed ID: 31214177 [TBL] [Abstract][Full Text] [Related]
12. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Bald T; Krummel MF; Smyth MJ; Barry KC Nat Immunol; 2020 Aug; 21(8):835-847. PubMed ID: 32690952 [TBL] [Abstract][Full Text] [Related]
13. Leveraging epigenetics to enhance the efficacy of immunotherapy. Licht JD; Bennett RL Clin Epigenetics; 2021 May; 13(1):115. PubMed ID: 34001289 [TBL] [Abstract][Full Text] [Related]
14. [Unleashing NK cell signaling to improve cancer immunotherapy]. Bernard PL; Laletin V; Pastor S; Nunès JA; Guittard G Med Sci (Paris); 2020 Oct; 36 Hors série n° 1():50-55. PubMed ID: 33052095 [No Abstract] [Full Text] [Related]
17. Natural killer cells and cancer therapy, what we know and where we are going. Ghaemdoust F; Keshavarz-Fathi M; Rezaei N Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725 [TBL] [Abstract][Full Text] [Related]
18. Natural killer cell engineering - a new hope for cancer immunotherapy. Lin CY; Gobius I; Souza-Fonseca-Guimaraes F Semin Hematol; 2020 Oct; 57(4):194-200. PubMed ID: 33256912 [TBL] [Abstract][Full Text] [Related]
19. Localization Matters: Epigenetic Regulation of Natural Killer Cells in Different Tissue Microenvironments. Wiedemann GM Front Immunol; 2022; 13():913054. PubMed ID: 35707540 [TBL] [Abstract][Full Text] [Related]
20. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. Matosevic S J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]